Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Kaneno, Ramon ^a   Shurin, Galina V ^b   Tourkova, Irina L ^b   Shurin, Michael R ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; BLEOMYCIN SULFATE; CARBOPLATIN; CD40 ANTIGEN; CD83 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUTAMIDE; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MITOMYCIN C; MULGRAVE; PACLITAXEL; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE; LEUKOCYTE ANTIGEN; LIPOCORTIN 5;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL MATURATION; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SURVIVAL; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; HEAD AND NECK TUMOR; IC 50; MALE; METABOLISM; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TIME; TUMOR CELL LINE; UPREGULATION;

ANNEXIN A5; ANTIGENS, CD; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HEAD AND NECK NEOPLASMS; HLA-DR ANTIGENS; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOCYTE CULTURE TEST, MIXED; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TIME FACTORS; UP-REGULATION;

EID: 68349083269     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-58     Document Type: Article

References (50)

1. Andre T de Gramont A An overview of adjuvant systemic chemotherapy for colon cancer Clinical colorectal cancer 2004, 4(Suppl 1):S22-28. 10.3816/ CCC.2004.s.004 15212702
2. Valentini AM Armentano R Pirrelli M Caruso ML Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art Cancer treatment reviews 2006, 32(8):607-618. 10.1016/ j.ctrv.2006.08.001 17055172
3. Baruchel S Stempak D Low-dose metronomic chemotherapy: myth or truth? Onkologie 2006, 29(7):305-307. 10.1159/000093971 16874013
4. McWhinney SR Goldberg RM McLeod HL Platinum neurotoxicity pharmacogenetics Molecular cancer therapeutics 2009, 8(1):10-16. 10.1158/ 1535-7163.MCT-08-0840 19139108
5. Vento S Cainelli F Temesgen Z Lung infections after cancer chemotherapy The lancet oncology 2008, 9(10):982-992. 10.1016/S1470-2045(08)70255-9 19071255
6. Khakoo AY Yeh ET Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy Nature clinical practice 2008, 5(11):655-667. 10.1038/ncponc1225 18797437
7. Klement G Baruchel S Rak J Man S Clark K Hicklin DJ Bohlen P Kerbel RS Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity The Journal of clinical investigation 2000, 105(8):R15-24. 517491 10772661 10.1172/JCI8829
8. Browder T Butterfield CE Kraling BM Shi B Marshall B O'Reilly MS Folkman J Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer research 2000, 60(7):1878-1886. 10766175
9. Apetoh L Ghiringhelli F Tesniere A Obeid M Ortiz C Criollo A Mignot G Maiuri MC Ullrich E Saulnier P Yang H Amigorena S Ryffel B Barrat FJ Saftig P Levi F Lidereau R Nogues C Mira JP Chompret A Joulin V Clavel-Chapelon F Bourhis J Andre F Delaloge S Tursz T Kroemer G Zitvogel L Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature medicine 2007, 13(9):1050-1059. 10.1038/nm1622 17704786
10. Apetoh L Ghiringhelli F Tesniere A Criollo A Ortiz C Lidereau R Mariette C Chaput N Mira JP Delaloge S Andre F Tursz T Kroemer G Zitvogel L The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy Immunological reviews 2007, 220:47-59. 10.1111/j.1600-065X.2007.00573.x 17979839
11. Zhong H Shurin MR Han B Optimizing dendritic cell-based immunotherapy for cancer Expert review of vaccines 2007, 6(3):333-345. 10.1586/ 14760584.6.3.333 17542749
12. Chao D Bahl P Houlbrook S Hoy L Harris A Austyn JM Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay Br J Cancer 1999, 81(8):1280-1284. 10.1038/ sj.bjc.6694366 10604723
13. Perrotta C Bizzozero L Falcone S Rovere-Querini P Prinetti A Schuchman EH Sonnino S Manfredi AA Clementi E Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma Cancer research 2007, 67(16):7559-7564. 10.1158/ 0008-5472.CAN-07-0309 17699758
14. Shin JY Lee SK Kang CD Chung JS Lee EY Seo SY Lee SY Baek SY Kim BS Kim JB Yoon S Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model Histol Histopathol. 2003, 18(2):435-447. 12647794
15. Nakashima H Tasaki A Kubo M Kuroki H Matsumoto K Tanaka M Nakamura M Morisaki T Katano M Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells Cancer Chemother Pharmacol 2005, 55(5):479-487. 10.1007/s00280-004-0918-7 15726369
16. Jiga LP Bauer TM Chuang JJ Opelz G Terness P Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86 Transplantation 2004, 77(11):1761-1764. 10.1097/ 01.TP.0000131165.37177.6E 15201679
17. Laane E Bjorklund E Mazur J Lonnerholm G Soderhall S Porwit A Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia Scandinavian journal of immunology 2007, 66(5):572-583. 10.1111/j.1365-3083.2007.02007.x 17892461
18. Wertel I Polak G Barczynski B Kotarski J [Subpopulations of peripheral blood dendritic cells during chemotherapy of ovarian cancer] Ginekologia polska 2007, 78(10):768-771. 18200966 cancer
19. Bellik L Gerlini G Parenti A Ledda F Pimpinelli N Neri B Pantalone D Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer Clinical immunology (Orlando, Fla) 2006, 121(1):74-80. 10.1016/j.clim.2006.06.011 16914380
20. Shurin GV Tourkova IL Shurin MR Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells J Immunother 2008, 31(5):491-499. 10.1097/CJI.0b013e318176fae4 18463535
21. Shurin GV Amina N Shurin MR Cancer therapy and dendritic cell immunomodulation Dendritic Cells in Cancer New York: Springer Salter RD 2009:201-216.
22. Shurin GV Tourkova IL Kaneno R Shurin MR Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J Immunol 2009, 183:137-144. 10.4049/jimmunol.0900734 19535620
23. Melief CJ Cancer immunotherapy by dendritic cells Immunity 2008, 29(3):372-383. 10.1016/j.immuni.2008.08.004 18799145
24. Dong Xda E Ito N Lotze MT Demarco RA Popovic P Shand SH Watkins S Winikoff S Brown CK Bartlett DL Zeh HJ 3rd High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy J Immunother 2007, 30(6):596-606. 10.1097/CJI.0b013e31804efc76 17667523
25. Most van der RG Currie AJ Robinson BW Lake RA Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all Cell death and differentiation 2008, 15(1):13-20. 10.1038/ sj.cdd.4402255
26. Bauer C Bauernfeind F Sterzik A Orban M Schnurr M Lehr HA Endres S Eigler A Dauer M Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut 2007, 56(9):1275-1282. 10.1136/gut.2006.108621 17395611
27. Choi GS Lee MH Kim SK Kim CS Lee HS Im MW Kil HY Seong DH Lee JR Kim WC Lee MG Song SU Combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (Paclitaxel) for murine fibrosarcoma Yonsei medical journal 2005, 46(6):835-842. 16385661,
28. Zhong H Han B Tourkova IL Lokshin A Rosenbloom A Shurin MR Shurin GV Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth Clin Cancer Res 2007, 13(18 Pt 1):5455-5462. 2474691 17875775 10.1158/ 1078-0432.CCR-07-0517
29. Gabrilovich DI Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited The lancet oncology 2007, 8(1):2-3. 10.1016/ S1470-2045(06)70985-8 17196504
30. Cavanagh WA Tjoa BA Ragde H Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment Urology 2007, 70(6 Suppl):36-41. 10.1016/ j.urology.2007.06.1127 18194710
31. Shurin MR Preparation of human dendritic cells for tumor vaccination Methods in Molecular Biology 2003, 215:437-462. 12512319
32. Pirtskhalaishvili G Shurin GV Esche C Cai Q Salup RR Bykovskaia SN Lotze MT Shurin MR Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins Br J Cancer 2000, 83(4):506-513. 10.1054/bjoc.2000.1289 10945499
33. Tourkova IL Yurkovetsky ZR Shurin MR Shurin GV Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay Immunol Lett 2001, 78(2):75-82. 10.1016/S0165-2478(01)00235-8 11672590
34. Steinman RM Witmer MD Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice Proc Natl Acad Sci USA 1978, 75(10):5132-5136. 336278 154105 10.1073/pnas.75.10.5132
35. Schlom J Arlen PM Gulley JL Cancer vaccines: moving beyond current paradigms Clin Cancer Res 2007, 13(13):3776-3782. 2536755 17606707 10.1158/1078-0432.CCR-07-0588
36. Nowak AK Lake RA Robinson BW Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 2006, 58(8):975-990. 10.1016/j.addr.2006.04.002 17005292
37. Nowak AK Lake RA Marzo AL Scott B Heath WR Collins EJ Frelinger JA Robinson BW Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 2003, 170(10):4905-4913. 12734333
38. Liu JY Wu Y Zhang XS Yang JL Li HL Mao YQ Wang Y Cheng X Li YQ Xia JC Masucci M Zeng YX Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine Cancer Immunol Immunother 2007, 56(10):1597-1604. 10.1007/s00262-007-0305-4 17440723
39. Brouwer E Verweij J De Bruijn P Loos WJ Pillay M Buijs D Sparreboom A Measurement of fraction unbound paclitaxel in human plasma Drug metabolism and disposition: the biological fate of chemicals 2000, 28(10):1141-1145. 10997930
40. Stempak D Gammon J Halton J Moghrabi A Koren G Baruchel S A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors J Pediatr Hematol Oncol 2006, 28(11):720-728. 10.1097/01.mph.0000243657.64056.c3 17114958
41. Vacca A Iurlaro M Ribatti D Minischetti M Nico B Ria R Pellegrino A Dammacco F Antiangiogenesis is produced by nontoxic doses of vinblastine Blood 1999, 94(12):4143-4155. 10590059
42. Lutsiak ME Semnani RT De Pascalis R Kashmiri SV Schlom J Sabzevari H Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005, 105(7):2862-2868. 10.1182/blood-2004-06-2410 15591121
43. Banissi C Ghiringhelli F Chen L Carpentier AF Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model Cancer Immunol Immunother 2009 19221744
44. Tanaka F Yamaguchi H Ohta M Mashino K Sonoda H Sadanaga N Inoue H Mori M Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo Int J Cancer 2002, 101(3):265-269. 10.1002/ijc.10597 12209978
45. Green DR Ferguson T Zitvogel L Kroemer G Immunogenic and tolerogenic cell death Nature reviews 2009, 9(5):353-363. 10.1038/nri2545 19365408
46. Ottaiano A Pisano C De Chiara A Ascierto PA Botti G Barletta E Apice G Gridelli C Iaffaioli VR CD40 activation as potential tool in malignant neoplasms Tumori 2002, 88(5):361-366. 12487551
47. Tong AW Papayoti MH Netto G Armstrong DT Ordonez G Lawson JM Stone MJ Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer Clin Cancer Res 2001, 7(3):691-703. 11297266
48. Shurin MR Yurkovetsky ZR Tourkova IL Balkir L Shurin GV Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10 Int J Cancer 2002, 101(1):61-68. 10.1002/ijc.10576 12209589
49. Esche C Gambotto A Satoh Y Gerein V Robbins PD Watkins SC Lotze MT Shurin MR CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth European journal of immunology 1999, 29(7):2148-2155. 10.1002/(SICI)1521-4141(199907)29:07<2148::AID- IMMU2148>3.0.CO;2-F10427977
50. Pinzon-Charry A Schmidt CW Lopez JA The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction Breast Cancer Res 2006, 8(1):402. 1413976 16524455 10.1186/bcr1386